| Q35227509 | A Comparison of Regulatory Features in Primate Lentiviruses |
| Q35189274 | A Rev-inducible mutant gag gene stably transferred into T lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 infection |
| Q40409944 | A circular trans-acting hepatitis delta virus ribozyme |
| Q37311199 | A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread |
| Q40428153 | A defective HIV-1 vector for gene transfer to human lymphocytes |
| Q34159206 | A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo |
| Q28260418 | A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1 |
| Q37587432 | A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins |
| Q39872193 | A nonproducer, interfering human immunodeficiency virus (HIV) type 1 provirus can be transduced through a murine leukemia virus-based retroviral vector: recovery of an anti-HIV mouse/human pseudotype retrovirus. |
| Q34391750 | A nucleolar TAR decoy inhibitor of HIV-1 replication. |
| Q37202396 | A role for NF-kappaB-dependent gene transactivation in sunburn. |
| Q77314513 | A simple assay system for examination of the inhibitory potential in vivo of decoy RNAs, ribozymes and other drugs by measuring the Tat-mediated transcription of a fusion gene composed of the long terminal repeat of HIV-1 and a gene for luciferase |
| Q39717672 | A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription |
| Q40925893 | AIDS-related Kaposi's sarcoma. A template for the translation of molecular pathogenesis into targeted therapeutic approaches |
| Q40396975 | Activation and inactivation of gene expression using RNA sequences |
| Q38995729 | Advances in the development of aptamer drug conjugates for targeted drug delivery |
| Q35851955 | Altered cytokine expression in T lymphocytes from human immunodeficiency virus Tat transgenic mice |
| Q36828521 | Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation |
| Q39594158 | Anti-Rex aptamers as mimics of the Rex-binding element. |
| Q41563534 | Anti-gene therapy: the use of ribozymes to inhibit gene function |
| Q38297215 | Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects |
| Q30470240 | Aptamers and their biological applications |
| Q39070782 | Aptamers as Therapeutics |
| Q89939220 | Aptamers as Versatile Ligands for Biomedical and Pharmaceutical Applications |
| Q38299974 | Aptamers as potential nucleic acid pharmaceuticals. |
| Q36538095 | Aptamers come of age - at last |
| Q37160512 | Aptamers in immunotherapy |
| Q35086493 | Aptamers: active targeting ligands for cancer diagnosis and therapy |
| Q42181807 | Aptamers: novel molecules as diagnostic markers in bacterial and viral infections? |
| Q92864734 | At the Intersection of Biomaterials and Gene Therapy: Progress in Non-viral Delivery of Nucleic Acids |
| Q30848680 | Bi-functional, substrate mimicking RNA inhibits MSK1-mediated cAMP-response element-binding protein phosphorylation and reveals magnesium ion-dependent conformational changes of the kinase |
| Q38358539 | Binding of intracellular anti-Rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: variations in viral inhibition |
| Q36193108 | Blockade of human immunodeficiency virus type 1 production in CD4+ T cells by an intracellular CD4 expressed under control of the viral long terminal repeat |
| Q26801765 | Bone Marrow Gene Therapy for HIV/AIDS |
| Q47236016 | Cell and Gene Therapy for HIV Cure |
| Q39881018 | Cell and viral regulatory elements enhance the expression and function of a human immunodeficiency virus inhibitory gene |
| Q38529069 | Cell-based gene therapy against HIV. |
| Q38272165 | Cell-specific aptamers and their conjugation with nanomaterials for targeted drug delivery |
| Q35742703 | Characterization of a "kissing" hairpin complex derived from the human immunodeficiency virus genome |
| Q41576182 | Characterization of the inducer of short transcripts, a human immunodeficiency virus type 1 transcriptional element that activates the synthesis of short RNAs. |
| Q37939984 | Chimeric aptamers in cancer cell-targeted drug delivery |
| Q54578898 | Circular ribozymes generated in Escherichia coli using group I self-splicing permuted intron-exon sequences. |
| Q34669645 | Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication |
| Q35542605 | Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody |
| Q39577700 | Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication |
| Q40045233 | Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. |
| Q35174403 | Correlations Between theIn VitroandIn VivoActivity of Anti-HIV Agents: Implications for Future Drug Deyelopment |
| Q24652403 | Crystal structure of an RNA aptamer bound to thrombin |
| Q38168595 | Current progress on aptamer-targeted oligonucleotide therapeutics |
| Q36143446 | Current status of gene therapy strategies to treat HIV/AIDS. |
| Q34244510 | Current status of retroviral vector mediated gene transfer into human hematopoietic stem cells |
| Q28379462 | Decoy approach using RNA-DNA chimera oligonucleotides to inhibit the regulatory function of human immunodeficiency virus type 1 Rev protein |
| Q40432041 | Developing aptamers into therapeutics |
| Q34433842 | Development of universal antidotes to control aptamer activity. |
| Q40041905 | Effects of human chromosome 12 on interactions between Tat and TAR of human immunodeficiency virus type 1. |
| Q34365376 | Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes |
| Q36634983 | Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. |
| Q42451949 | Efficient retroviral gene transfer of a Tat-regulated herpes simplex virus thymidine kinase gene for HIV gene therapy. |
| Q28214164 | Emerging clinical applications of RNA |
| Q38362885 | Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. |
| Q35800195 | Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals |
| Q45869627 | Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-kappa B/Rel- specific decoy oligodeoxynucleotides |
| Q35305398 | Examples of expression systems based on animal RNA viruses: alphaviruses and influenza virus |
| Q41381148 | Expression of a Tat-inducible herpes simplex virus-thymidine kinase gene protects acyclovir-treated CD4 cells from HIV-1 spread by conditional suicide and inhibition of reverse transcription. |
| Q37679611 | Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients |
| Q38851919 | From the RNA world to the clinic |
| Q59257306 | Full expression of transfected nonproducer interfering HIV-1 proviral DNAabrogates susceptibility of human He-La CD4+ cells to HIV |
| Q43162983 | Furan-modified oligonucleotides for fast, high-yielding and site-selective DNA inter-strand cross-linking with non-modified complements |
| Q34595695 | Fusion with an RNA binding domain to confer target RNA specificity to an RNase: design and engineering of Tat-RNase H that specifically recognizes and cleaves HIV-1 RNA in vitro |
| Q40476400 | Gene therapeutic agents: The use of ribozymes, antisense, and RNA decoys for HIV-1 infection |
| Q33579411 | Gene therapy for AIDS. |
| Q40138988 | Gene therapy for HIV infections: Intracellular immunization |
| Q34208320 | Gene therapy for HIV. |
| Q33992464 | Gene therapy for infectious diseases |
| Q40841565 | Gene transfer for therapy and prophylaxis of HIV-1 infection |
| Q33636597 | Genetic engineering for xenotransplantation |
| Q33739314 | Genetic strategies to inhibit HIV. |
| Q38311335 | H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity. |
| Q33857478 | HIV protease as a target for retrovirus vector-mediated gene therapy |
| Q44351237 | HIV-1 proprotein processing as a target for gene therapy. |
| Q37021788 | HIV/AIDS eradication |
| Q37556169 | HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines |
| Q36139325 | High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency. |
| Q36220668 | Human gene therapy comes of age. |
| Q33541775 | Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. |
| Q34757765 | Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter. |
| Q37775492 | In vitro and ex vivo selection procedures for identifying potentially therapeutic DNA and RNA molecules. |
| Q34362307 | In vitro selection identifies key determinants for loop-loop interactions: RNA aptamers selective for the TAR RNA element of HIV-1. |
| Q35762528 | In vivo identification of a negative regulatory element in the mouse renin gene using direct gene transfer |
| Q38300522 | In vivo reduction of the nuclear factor-kappaB activity using synthetic cis-element decoy oligonucleotides suppresses intimal hyperplasia in the injured carotid arteries in rabbits |
| Q38343941 | In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction |
| Q42467137 | Inducible expression of herpes simplex virus thymidine kinase from a bicistronic HIV1 vector |
| Q36915653 | Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation |
| Q42468168 | Inhibition of HIV Production in Cells Containing an Integrated, HIV-Regulated Diphtheria Toxin A Chain Gene |
| Q24568329 | Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies |
| Q24793909 | Inhibition of HIV-1 gene expression by retroviral vector-mediated small-guide RNAs that direct specific RNA cleavage by tRNase ZL |
| Q40237715 | Inhibition of HIV-1 replication by simian restriction factors, TRIM5alpha and APOBEC3G. |
| Q35840768 | Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes. |
| Q40578485 | Inhibition of hepatitis C virus IRES-mediated translation by small RNAs analogous to stem-loop structures of the 5'-untranslated region. |
| Q40378542 | Inhibition of hepatitis C virus replication by pol III-directed overexpression of RNA decoys corresponding to stem-loop structures in the NS5B coding region |
| Q33830704 | Inhibition of hepatitis C virus replication by single-stranded RNA structural mimics |
| Q44526946 | Inhibition of human immunodeficiency virus expression by sense transcripts encoding the retroviral leader RNA |
| Q36638137 | Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain. |
| Q38333070 | Inhibition of human immunodeficiency virus type 1 multiplication by antisense and sense RNA expression |
| Q36504080 | Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. |
| Q37256308 | Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator |
| Q37383055 | Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo |
| Q34634265 | Inhibition of transcription by the TAR RNA of HIV-1 in a nuclear extract of HeLa cells |
| Q27490949 | Inhibition of west nile virus replication by retrovirus-delivered small interfering RNA in human neuroblastoma cells |
| Q39877337 | Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type 1 gag gene inhibits viral replication in human CD4+ lymphocytes. |
| Q71803471 | Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro |
| Q38324355 | Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model |
| Q35663424 | Is gene therapy a good therapeutic approach for HIV-positive patients? |
| Q73077132 | Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies |
| Q36367219 | Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes |
| Q35059839 | Isolation of dominant negative mutants and inhibitory antisense RNA sequences by expression selection of random DNA fragments |
| Q41240955 | Kinetics of retroviral production from the amphotropic ΨCRIP murine producer cell line |
| Q47098902 | Latent HIV-1 TAR Regulates 7SK-responsive P-TEFb Target Genes and Targets Cellular Immune Responses in the Absence of Tat. |
| Q27651054 | Liquid-crystal NMR structure of HIV TAR RNA bound to its SELEX RNA aptamer reveals the origins of the high stability of the complex |
| Q38641303 | Long Noncoding RNAs in Cancer and Therapeutic Potential. |
| Q42548704 | Modulation of the Rev-RRE interaction by aromatic heterocyclic compounds |
| Q37314633 | Molecular decoys: antidotes, therapeutics and immunomodulators |
| Q91912081 | Molecular recognition elements: DNA/RNA-aptamers to proteins |
| Q35881105 | Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades |
| Q34033118 | Multiple biological roles associated with the repeat (R) region of the HIV-1 RNA genome |
| Q36460842 | Nanoparticle-aptamer bioconjugates for cancer targeting. |
| Q35924105 | Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells |
| Q38256244 | Nucleic acid aptamer-mediated drug delivery for targeted cancer therapy |
| Q37586838 | Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics. |
| Q26849947 | Nucleic acid aptamers: an emerging frontier in cancer therapy |
| Q34028112 | Nucleic acid aptamers: clinical applications and promising new horizons |
| Q37857036 | Nucleic acid based molecular devices |
| Q37833455 | Oligomeric nucleic acids as antivirals. |
| Q39685303 | Optimized chimeras between kinase-inactive mutant Cdk9 and truncated cyclin T1 proteins efficiently inhibit Tat transactivation and human immunodeficiency virus gene expression |
| Q40043226 | Orientation-specific cis complementation by bulge- and loop-mutated human immunodeficiency virus type 1 TAR RNAs. |
| Q35142045 | Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells |
| Q45755417 | Positive selection system to screen for inhibitors of human immunodeficiency virus-1 transcription |
| Q35261143 | Possibilities for RNA interference in developing hepatitis C virus therapeutics |
| Q35921730 | Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction. |
| Q35365812 | Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody |
| Q39683830 | Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). |
| Q41661268 | Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer |
| Q38267240 | Potential mechanisms for cell-based gene therapy to treat HIV/AIDS. |
| Q40405021 | Progress in anti-HIV structure-based drug design |
| Q35613156 | RNA aptamers as effective protein antagonists in a multicellular organism |
| Q34457815 | RNA aptamers directed to human immunodeficiency virus type 1 Gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus production |
| Q61480518 | RNA interference: from an ancient mechanism to a state of the art therapeutic application? |
| Q39724951 | RNA mimetics: oligoribonucleotide N3'-->P5' phosphoramidates |
| Q34459382 | RNA-based gene therapy for HIV infection |
| Q39877972 | RNA-targeted activators, but not DNA-targeted activators, repress the synthesis of short transcripts at the human immunodeficiency virus type 1 long terminal repeat. |
| Q35907032 | Regulatable aptamers in medicine: focus on antithrombotic strategies |
| Q40467663 | Regulation of HIV-1 Gene Expression by the Transactivator Protein Tat |
| Q40756505 | Regulation of human immunodeficiency virus infection: implications for pathogenesis |
| Q34042038 | Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs. |
| Q45878407 | SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters. |
| Q30463953 | Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor |
| Q35740074 | Selective Targeting to Glioma with Nucleic Acid Aptamers |
| Q36763035 | Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population |
| Q35019143 | Selective optimization of the Rev-binding element of HIV-1. |
| Q40432046 | Series introduction: emerging clinical applications of nucleic acids |
| Q34961807 | Specific ablation of human immunodeficiency virus Tat-expressing cells by conditionally toxic retroviruses |
| Q37313430 | Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment |
| Q73295842 | Specific inhibition of in vitro reverse transcription using antisense oligonucleotides targeted to the TAR regions of HIV-1 and HIV-2 |
| Q41981808 | Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication |
| Q35241689 | Status of ribozyme and antisense-based developmental approaches for anti-HIV-1 therapy |
| Q34769333 | Stem cell-based anti-HIV gene therapy |
| Q33702807 | Strategies to express structural and catalytic RNAs in mammalian cells |
| Q27733920 | Structure of HIV-1 TAR RNA in the absence of ligands reveals a novel conformation of the trinucleotide bulge |
| Q41614987 | Suppression of gene expression in plant cells utilizing antisense sequences transcribed by RNA polymerase III. |
| Q42848859 | TAR RNA decoys inhibit tat-activated HIV-1 transcription after preinitiation complex formation |
| Q38337003 | TAR-RNA binding by HIV-1 Tat protein is selectively inhibited by its L-enantiomer |
| Q34200458 | Targeted and highly efficient gene transfer into CD4+ cells by a recombinant human immunodeficiency virus retroviral vector |
| Q24810050 | Targeted disruption of transcriptional regulatory function of p53 by a novel efficient method for introducing a decoy oligonucleotide into nuclei. |
| Q90529594 | Targeting of G-protein coupled receptors in sepsis |
| Q40309266 | Tat- and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: a temporal analysis. |
| Q34195783 | Tat-independent replication of human immunodeficiency viruses |
| Q40854213 | The biochemistry of gene therapy for AIDS. |
| Q58273726 | The middle to 3′ end of the HIV-1 Vif gene sequence is important for Vif biological activity and could be used for antisense oligonucleotide targets |
| Q35276631 | The pathogenesis of AIDS lymphomas: a foundation for addressing the challenges of therapy and prevention |
| Q37571996 | Therapeutic applications of DNA and RNA aptamers. |
| Q40393204 | Therapy Other Than Reverse Transcriptase Inhibitors for HIV Infection |
| Q38309939 | Transcription factor decoy for NFkappaB inhibits TNF-alpha-induced cytokine and adhesion molecule expression in vivo |
| Q38300047 | Transcription factor decoy: a pre-transcriptional approach for gene downregulation purpose in cancer |
| Q41381095 | Transcriptional inhibition of the parvovirus minute virus of mice by constitutive expression of an antisense RNA targeted against the NS-1 transactivator protein |
| Q35863619 | Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture |
| Q44325003 | Transfection of NFkappaB-decoy oligodeoxynucleotides using efficient ultrasound-mediated gene transfer into donor kidneys prolonged survival of rat renal allografts |
| Q38324836 | Treatment of experimental asthma by decoy-mediated local inhibition of activator protein-1. |
| Q39869106 | Use of a human immunodeficiency virus type 1 Rev mutant without nucleolar dysfunction as a candidate for potential AIDS therapy. |
| Q27486214 | Utilization of heterologous alphavirus junction sequences as promoters by Sindbis virus |